



Supplemental material

Hosokawa et al., https://doi.org/10.1084/jem.20190972

\$JEM



Figure S1. **Characterization of ILC2 and pro-T cell transcriptomes, Runx binding patterns, Bcl11b modifications, and activities in the Bcl11b enhancer region. (A)** Heat maps show hierarchical clustering analyses of the expression of all expressed genes, which have RPKM >3 in naive ILC2 cells or an ILC2 cell line, ILC2/b6 cells, in naive ILC2, stimulated ILC2 for 4 h or 7 d (Shih et al., 2016; Yagi et al., 2014), and ILC2/b6 cells. **(B)** Representative RNA-seq tracks are shown for *Bcl11b*-deficient Scid.adh.2c2 or ILC2/b6 cells at the *Bcl11b* locus (around exon1 and 2). Red arrowheads show sites against which sgRNA was designed. **(C)** Tag count distributions for Bcl11b, Runx1, Runx3, and GATA3 in Scid.adh.2c2 and ILC2/b6 cells are shown. All Bcl11b and GATA3 binding sites identified in the DN3 and ILC2/b6 cells were included in the analysis. **(D)** Venn diagrams show the number of Runx3 ChIP peaks in Scid.adh.2c2 and ILC2/b6 cells with Bcl11b ChIP peaks in Scid.adh.2c2 cells (top) or ILC2/b6 cells (bottom). **(F)** Post-translational modifications of Bcl11b protein detected by mass spectrometry analysis are shown. **(G)** Representative ATAC-seq tracks for thymic DN subsets and mature small intestine ILC2 cells (Yoshida et al., 2019; downloaded from GEO accession no. GSE100738) and binding profiles of Bcl11b in DN3, Scid.adh.2c2, and ILC2/b6 cells are shown around the Bcl11b major peak enhancer (magenta rectangle) and *ThymoD* locus. The low activity state shown here in mature ILC2 cells contrasts with the state inferred to exist in ILC2 precursors, based on evidence in Fig. 5. **(H)** Representative RNA-seq tracks (mapped with STAR v2.4.0) at the *ThymoD* locus are shown for thymic DN subsets (Yoshida et al., 2019; GSE100738), in vitro cultured bone marrow precursor-derived DN3, Scid.adh.2c2, mature naive ILC2, mature ILC2 stimulated (stim.) for 4 h or 7 d (Shih et al., 2016; Yagi et al., 2014), and ILC2/b6 cells. Data from this study are based on two replicate RNA-seq results (A, B, and H) and are based on reproduc

Hosokawa et al. Action of Bcl11b in pro-T and ILC2 cells



Tables S1 and S2 are provided online as separate Excel files. Table S1 shows DEGs after Cas9-mediated disruption of Bcl11b gene in Scid.adh.2c2 and ILC2/b6 cells. Table S2 shows Bcl11b-interacting molecules in Scid.adh.2c2 and ILC2/b6 cells identified by LC-MS/MS.

References

- Hosokawa, H., M. Romero-Wolf, M.A. Yui, J. Ungerbäck, M.L.G. Quiloan, M. Matsumoto, K.I. Nakayama, T. Tanaka, and E.V. Rothenberg. 2018a. Bcl11b sets pro-T cell fate by site-specific cofactor recruitment and by repressing Id2 and Zbtb16. *Nat. Immunol.* 19:1427–1440. https://doi.org/10.1038/s41590-018 -0238-4
- Shih, H.Y., G. Sciumè, Y. Mikami, L. Guo, H.W. Sun, S.R. Brooks, J.F. Urban Jr., F.P. Davis, Y. Kanno, and J.J. O'Shea. 2016. Developmental acquisition of regulomes underlies innate lymphoid cell functionality. *Cell*. 165:1120–1133. https://doi.org/10.1016/j.cell.2016.04.029
- Yagi, R., C. Zhong, D.L. Northrup, F. Yu, N. Bouladoux, S. Spencer, G. Hu, L. Barron, S. Sharma, T. Nakayama, et al. 2014. The transcription factor GATA3 is critical for the development of all IL-7Rα-expressing innate lymphoid cells. *Immunity*. 40:378–388. https://doi.org/10.1016/j.immuni.2014.01.012

Yoshida, H., C.A. Lareau, R.N. Ramirez, S.A. Rose, B. Maier, A. Wroblewska, F. Desland, A. Chudnovskiy, A. Mortha, C. Dominguez, et al. Immunological Genome Project. 2019. The cis-regulatory atlas of the mouse immune system. *Cell*. 176:897–912.e20. https://doi.org/10.1016/j.cell.2018.12.036